Developments in US Antitrust Litigation—2020 Year in Review
Arnold Porter
JUNE 2, 2021
The Third Circuit rejected plaintiffs' argument, holding that Tyson did not control and confirming the long-standing Third Circuit rule that a class must demonstrate that its claims are capable of common proof at trial by a preponderance of the evidence.[[N: at 191-192.]] at 193-194.]]. In re Humira (Adalimumab) Antitrust Litigation.
98 
Let's personalize your content